{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T22:20:26Z","timestamp":1770070826881,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00296-021-04928-x","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T10:02:51Z","timestamp":1625047371000},"page":"1043-1051","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long-term survival of biological therapy in psoriatic arthritis: 18-year analysis of a cohort in a tertiary hospital"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6394-2949","authenticated-orcid":false,"given":"Lourdes","family":"Mateo Soria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1gueda","family":"Prior-Espa\u00f1ol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihail Mihaylov","family":"Grigorov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Holgado-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Aparicio-Espinar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melania","family":"Martinez-Morillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Oliv\u00e9-Marqu\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"4928_CR1","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/art.30117","volume":"63","author":"B Glintborg","year":"2011","unstructured":"Glintborg B, \u00d8stergaard M, Dreyer L et al (2011) Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor \u03b1 therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 63:382\u2013390. https:\/\/doi.org\/10.1002\/art.30117","journal-title":"Arthritis Rheum"},{"key":"4928_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/rheumatology\/kex387","volume":"57","author":"C Stober","year":"2018","unstructured":"Stober C, Ye W, Guruparan T et al (2018) Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis. Rheumatology 57:158\u2013163. https:\/\/doi.org\/10.1093\/rheumatology\/kex387","journal-title":"Rheumatology"},{"key":"4928_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/ar1941","volume":"8","author":"L Carmona","year":"2006","unstructured":"Carmona L, G\u00f3mez-Reino JJ (2006) Survival of TNF antagonists in spondyloarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 8:72. https:\/\/doi.org\/10.1186\/ar1941","journal-title":"Arthritis Res Ther"},{"key":"4928_CR4","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.reumae.2018.11.016","volume":"16","author":"JD Ca\u00f1ete","year":"2020","unstructured":"Ca\u00f1ete JD, Naranjo A, Calvo J et al (2020) Biological treatment patterns in patients with inflammatory joint diseases. Retrospective study with 4 years follow-up. Reumatol Cl\u00ednica Engl Ed 16:447\u2013454. https:\/\/doi.org\/10.1016\/j.reumae.2018.11.016","journal-title":"Reumatol Cl\u00ednica Engl Ed"},{"key":"4928_CR5","doi-asserted-by":"publisher","first-page":"R52","DOI":"10.1186\/ar2670","volume":"11","author":"AA Saad","year":"2009","unstructured":"Saad AA, Ashcroft DM, Watson KD et al (2009) Persistence with anti-tumor necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 11:R52. https:\/\/doi.org\/10.1186\/ar2670","journal-title":"Arthritis Res Ther"},{"key":"4928_CR6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190815","author":"ML Thomas","year":"2020","unstructured":"Thomas ML, Shaddick G, Charlton R et al (2020) Tumour necrosis factor inhibitor monotherapy versus combination therapy for the treatment of psoriatic arthritis: combined analysis of European biologics databases. J Rheumatol. https:\/\/doi.org\/10.3899\/jrheum.190815","journal-title":"J Rheumatol"},{"key":"4928_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-eular.1804","volume":"79","author":"M Nissen","year":"2020","unstructured":"Nissen M (2020) CO-medication with a conventional synthetic DMARD in patients with axial spondyloarthritis is associated with improved retention of TNF inhibitors: results from The Eurospa Collaboration. Ann Rheum Dis 79:71","journal-title":"Ann Rheum Dis"},{"key":"4928_CR8","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.semarthrit.2016.09.005","volume":"46","author":"K Aaltonen","year":"2017","unstructured":"Aaltonen K, Heinonen A, Joensuu J et al (2017) Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: a prospective cohort study. Semin Arthritis Rheum 46:732\u2013739. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.09.005","journal-title":"Semin Arthritis Rheum"},{"key":"4928_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000181","volume":"1","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, Collier DH, Saunders KC et al (2015) Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the CORRONA registry. RMD Open 1:e000181. https:\/\/doi.org\/10.1136\/rmdopen-2015-000181","journal-title":"RMD Open"},{"key":"4928_CR10","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/art.37876","volume":"65","author":"B Glintborg","year":"2013","unstructured":"Glintborg B, \u00d8stergaard M, Krogh NS et al (2013) Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor \u03b1 inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum 65:1213\u20131223. https:\/\/doi.org\/10.1002\/art.37876","journal-title":"Arthritis Rheum"},{"key":"4928_CR11","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1136\/annrheumdis-2020-eular.2127","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Siebert S, Bergmans P et al (2020) SAT0398 persistence of ustekinumab (UST) or TNF inhibitor (TNFI) treatment in psoriatic arthritis (PsA): insights from the large, prospective, multinational, real-world PsABio cohort. Ann Rheum Dis 79:1149\u20131150. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.2127","journal-title":"Ann Rheum Dis"},{"key":"4928_CR12","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/annrheumdis-2020-eular.3777","volume":"79","author":"MS Chimenti","year":"2020","unstructured":"Chimenti MS, Fonti GL, Conigliaro P et al (2020) Fri0270 one-year effectiveness, retention rate and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicentre study. Ann Rheum Dis 79:720\u2013720. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.3777","journal-title":"Ann Rheum Dis"},{"key":"4928_CR13","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1136\/annrheumdis-2020-eular.3197","volume":"79","author":"EG Favalli","year":"2020","unstructured":"Favalli EG, Marchesoni A, Balduzzi S, Montecucco C, Lomater C, Crepaldi G (2020) Effectiveness and retention rate of secukinumab for psoriatic arthritis and axial spondyloarthritis: real-life data from the Italian LORHEN registry. Ann Rheum Dis 79:718","journal-title":"Ann Rheum Dis"},{"key":"4928_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/annrheumdis-2020-eular.4969","volume":"79","author":"M Cheila","year":"2020","unstructured":"Cheila M, Douglas K, Koutsianas C (2020) Fri0280 comparative drug survival of TNF inhibitors and secukinumab in biologic na\u00efve patients with ankylosing spondylitis and psoriatic arthritis. Ann Rheum Dis 79:727\u2013728. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.4969","journal-title":"Ann Rheum Dis"},{"key":"4928_CR15","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1136\/annrheumdis-2020-eular.5970","volume":"79","author":"I Villa-Blanco","year":"2020","unstructured":"Villa-Blanco I, Castro SA, Fern\u00e1ndez S et al (2020) Fri0291 safety and survival of secukinumab in spondyloarthritis and psoriatic arthritis: real-life data. a multicenter study. Ann Rheum Dis 79:734\u2013734. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.5970","journal-title":"Ann Rheum Dis"},{"key":"4928_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa710","author":"J-G Letarouilly","year":"2020","unstructured":"Letarouilly J-G, Flachaire B, Labadie C et al (2020) Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison. Rheumatol Oxf Engl. https:\/\/doi.org\/10.1093\/rheumatology\/keaa710","journal-title":"Rheumatol Oxf Engl"},{"key":"4928_CR17","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1007\/s00296-018-4144-8","volume":"38","author":"G Deza","year":"2018","unstructured":"Deza G, Notario J, Ferran M et al (2018) Long-term etanercept survival in patients with psoriatic arthritis: a multicenter retrospective analysis in daily clinical practice in Spain. Rheumatol Int 38:2037\u20132043. https:\/\/doi.org\/10.1007\/s00296-018-4144-8","journal-title":"Rheumatol Int"},{"key":"4928_CR18","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1002\/ddr.21192","volume":"75","author":"M Biggioggero","year":"2014","unstructured":"Biggioggero M, Favalli EG (2014) Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides: anti-TNF in inflammatory arthritides. Drug Dev Res 75:S38\u2013S41. https:\/\/doi.org\/10.1002\/ddr.21192","journal-title":"Drug Dev Res"},{"key":"4928_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13013","volume":"48","author":"F Iannone","year":"2018","unstructured":"Iannone F, Salaffi F, Fornaro M et al (2018) Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis in real-world settings. Eur J Clin Invest 48:e13013. https:\/\/doi.org\/10.1111\/eci.13013","journal-title":"Eur J Clin Invest"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04928-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-04928-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04928-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T07:03:02Z","timestamp":1653202982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-04928-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["4928"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-04928-x","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"assertion":[{"value":"7 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Document included.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}